Compare Trip.com Group Ltd (TCOM) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Trip.com Group Ltd vs GeneDx Holdings Corp — how do they compare? Trip.com Group Ltd trades at $38.7 (market cap $24.30B), while GeneDx Holdings Corp trades at $67.73 (market cap $2.04B). The key difference: Trip.com Group Ltd is far larger — about 11.9× GeneDx Holdings Corp's market cap, and Trip.com Group Ltd pays a 0.42% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Trip.com Group Ltd for 79 Days and GeneDx Holdings Corp for 19 Days on average.
| TCOM | WGS | |
|---|---|---|
Market Cap | $24.30B | $2.04B |
Volume | 1,885,560 | 659,215 |
Sector | Consumer Cyclical | Health |
52-Week High | $78.96 | $167.51 |
52-Week Low | $37.96 | $34.51 |
Typical Hold Time | 79 Days | 19 Days |
Enterprise Value | $16.46B | $2.08B |
Dividend Yield | 0.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Trip.com (TCOM) trades at $37.96, down 0.78% on the day, amid a bearish technical signal but strong fundamentals. The stock shows robust profitability with a 36.9% net income margin and trades at a low P/E of 7.36. Recent Q2 2026 earnings beat expectations, yet regulatory pressures and a challenging travel environment create headwinds. Analyst consensus remains strongly bullish with a $56.64 price target, indicating significant upside potential from current levels.
The outlook for TCOM balances strong earnings growth and attractive valuation against regulatory risks and market volatility. Investment opportunity lies in its dominant travel platform and international expansion, but investors face risks from antitrust penalties and competitive pressures. The stock's current discount to analyst targets presents a potential value opportunity if execution remains solid.
GeneDx (WGS) trades at $68.53, down 4.18% today amid bearish technical signals despite recent positive earnings surprises. The stock shows mixed fundamentals with strong revenue growth to $454M in 2026 but negative profitability metrics including -23.4% net margin. Recent developments include new genomic testing products and hospital partnerships, while analyst consensus remains strongly bullish with a $81 price target representing 18% upside potential.
The investment case balances strong analyst support and genomic testing market growth against persistent profitability challenges and negative cash flow trends. Key catalysts include Q3 2026 earnings due soon and continued execution on operational improvements, while risks center on margin recovery timeline and competitive pressures in the rapidly evolving genomics space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Trip.com Group Ltd
Trip.com is the largest online travel agent in China and is positioned to benefit from the country's rising demand for higher-margin outbound travel as passport penetration is only 12% in China. The company generated about 78% of sales from accommodation reservations and transportation ticketing in 2020. The rest of revenue comes from package tours and corporate travel. Prior to the pandemic in 2019, the company generated 25% of revenue from international business, which is important to its margin expansion. Most of sales come from websites and mobile platforms, while the rest come from call centers. The competes in a crowded OTA industry in China, including Meituan, Alibaba-backed Fliggy, Toncheng, and Qunar. The company was founded in 1999 and listed on the Nasdaq in December 2003.
Read more on TCOM →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
